Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease September 12, 2023
Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer September 11, 2023
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023 September 6, 2023
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME August 30, 2023
Longwood Healthcare Leaders to Convene Top Biotech and Pharmaceutical Leaders and Researchers August 15, 2023
